Cargando…

Survival Analyses for Patients With Surgically Resected Pancreatic Neuroendocrine Tumors by World Health Organization 2010 Grading Classifications and American Joint Committee on Cancer 2010 Staging Systems

In 2010, World Health Organization (WHO) reclassified pancreatic neuroendocrine tumors (p-NETs) into 4 main groups: neuroendocrine tumor G1 (NET G1), neuroendocrine tumor G2 (NET G2), neuroendocrine carcinoma G3 (NEC G3), mixed adeno and neuroendocrine carcinoma (MANEC). Clinical value of these newl...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Min, Ke, Neng-wen, Zeng, Lin, Zhang, Yi, Tan, Chun-lu, Zhang, Hao, Mai, Gang, Tian, Bo-le, Liu, Xu-bao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674199/
https://www.ncbi.nlm.nih.gov/pubmed/26632896
http://dx.doi.org/10.1097/MD.0000000000002156
_version_ 1782404878391312384
author Yang, Min
Ke, Neng-wen
Zeng, Lin
Zhang, Yi
Tan, Chun-lu
Zhang, Hao
Mai, Gang
Tian, Bo-le
Liu, Xu-bao
author_facet Yang, Min
Ke, Neng-wen
Zeng, Lin
Zhang, Yi
Tan, Chun-lu
Zhang, Hao
Mai, Gang
Tian, Bo-le
Liu, Xu-bao
author_sort Yang, Min
collection PubMed
description In 2010, World Health Organization (WHO) reclassified pancreatic neuroendocrine tumors (p-NETs) into 4 main groups: neuroendocrine tumor G1 (NET G1), neuroendocrine tumor G2 (NET G2), neuroendocrine carcinoma G3 (NEC G3), mixed adeno and neuroendocrine carcinoma (MANEC). Clinical value of these newly updated WHO grading criteria has not been rigorously validated. The authors aimed to evaluate the clinical consistency of the new 2010 grading classifications by WHO and the 2010 tumor-node metastasis staging systems by American Joint Committee on Cancer (AJCC) on survivals for patients with surgically resected p-NETs. Moreover, the authors would validate the prognostic value of both criteria for p-NETs. The authors retrospectively collected the clinicopathologic data of 120 eligible patients who were all surgically treated and histopathologically diagnosed as p-NETs from January 2004 to February 2014 in our single institution. The new WHO criteria were assigned to 4 stratified groups with a respective distribution of 62, 35, 17, and 6 patients. Patients with NET G1 or NET G2 obtained a statistically better survival compared with those with NEC G3 or MANEC (P < 0.001). Survivals of NET G1 was also better than those of NET G2 (P = 0.023), whereas difference of survivals between NEC G3 and MANEC present no obvious significance (P = 0.071). The AJCC 2010 staging systems were respectively defined in 61, 36, 12, and 11 patients for each stage. Differences of survivals of stage I with stage III and IV were significant (P < 0.001), as well as those of stage II with III and IV (P < 0.001); whereas comparisons of stage I with stage II and stage III with IV were not statistically significant (P = 0.129, P = 0.286; respectively). Together with radical resection, these 2 systems were both significant in univariate and multivariate analysis (P < 0.05). The newly updated WHO 2010 grading classifications and the AJCC 2010 staging systems could consistently reflect the clinical outcome of patients with surgically resected p-NETs. Meanwhile, both criteria could be independent predictors for survival analysis of p-NETs.
format Online
Article
Text
id pubmed-4674199
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-46741992015-12-14 Survival Analyses for Patients With Surgically Resected Pancreatic Neuroendocrine Tumors by World Health Organization 2010 Grading Classifications and American Joint Committee on Cancer 2010 Staging Systems Yang, Min Ke, Neng-wen Zeng, Lin Zhang, Yi Tan, Chun-lu Zhang, Hao Mai, Gang Tian, Bo-le Liu, Xu-bao Medicine (Baltimore) 4300 In 2010, World Health Organization (WHO) reclassified pancreatic neuroendocrine tumors (p-NETs) into 4 main groups: neuroendocrine tumor G1 (NET G1), neuroendocrine tumor G2 (NET G2), neuroendocrine carcinoma G3 (NEC G3), mixed adeno and neuroendocrine carcinoma (MANEC). Clinical value of these newly updated WHO grading criteria has not been rigorously validated. The authors aimed to evaluate the clinical consistency of the new 2010 grading classifications by WHO and the 2010 tumor-node metastasis staging systems by American Joint Committee on Cancer (AJCC) on survivals for patients with surgically resected p-NETs. Moreover, the authors would validate the prognostic value of both criteria for p-NETs. The authors retrospectively collected the clinicopathologic data of 120 eligible patients who were all surgically treated and histopathologically diagnosed as p-NETs from January 2004 to February 2014 in our single institution. The new WHO criteria were assigned to 4 stratified groups with a respective distribution of 62, 35, 17, and 6 patients. Patients with NET G1 or NET G2 obtained a statistically better survival compared with those with NEC G3 or MANEC (P < 0.001). Survivals of NET G1 was also better than those of NET G2 (P = 0.023), whereas difference of survivals between NEC G3 and MANEC present no obvious significance (P = 0.071). The AJCC 2010 staging systems were respectively defined in 61, 36, 12, and 11 patients for each stage. Differences of survivals of stage I with stage III and IV were significant (P < 0.001), as well as those of stage II with III and IV (P < 0.001); whereas comparisons of stage I with stage II and stage III with IV were not statistically significant (P = 0.129, P = 0.286; respectively). Together with radical resection, these 2 systems were both significant in univariate and multivariate analysis (P < 0.05). The newly updated WHO 2010 grading classifications and the AJCC 2010 staging systems could consistently reflect the clinical outcome of patients with surgically resected p-NETs. Meanwhile, both criteria could be independent predictors for survival analysis of p-NETs. Wolters Kluwer Health 2015-12-07 /pmc/articles/PMC4674199/ /pubmed/26632896 http://dx.doi.org/10.1097/MD.0000000000002156 Text en Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 4300
Yang, Min
Ke, Neng-wen
Zeng, Lin
Zhang, Yi
Tan, Chun-lu
Zhang, Hao
Mai, Gang
Tian, Bo-le
Liu, Xu-bao
Survival Analyses for Patients With Surgically Resected Pancreatic Neuroendocrine Tumors by World Health Organization 2010 Grading Classifications and American Joint Committee on Cancer 2010 Staging Systems
title Survival Analyses for Patients With Surgically Resected Pancreatic Neuroendocrine Tumors by World Health Organization 2010 Grading Classifications and American Joint Committee on Cancer 2010 Staging Systems
title_full Survival Analyses for Patients With Surgically Resected Pancreatic Neuroendocrine Tumors by World Health Organization 2010 Grading Classifications and American Joint Committee on Cancer 2010 Staging Systems
title_fullStr Survival Analyses for Patients With Surgically Resected Pancreatic Neuroendocrine Tumors by World Health Organization 2010 Grading Classifications and American Joint Committee on Cancer 2010 Staging Systems
title_full_unstemmed Survival Analyses for Patients With Surgically Resected Pancreatic Neuroendocrine Tumors by World Health Organization 2010 Grading Classifications and American Joint Committee on Cancer 2010 Staging Systems
title_short Survival Analyses for Patients With Surgically Resected Pancreatic Neuroendocrine Tumors by World Health Organization 2010 Grading Classifications and American Joint Committee on Cancer 2010 Staging Systems
title_sort survival analyses for patients with surgically resected pancreatic neuroendocrine tumors by world health organization 2010 grading classifications and american joint committee on cancer 2010 staging systems
topic 4300
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674199/
https://www.ncbi.nlm.nih.gov/pubmed/26632896
http://dx.doi.org/10.1097/MD.0000000000002156
work_keys_str_mv AT yangmin survivalanalysesforpatientswithsurgicallyresectedpancreaticneuroendocrinetumorsbyworldhealthorganization2010gradingclassificationsandamericanjointcommitteeoncancer2010stagingsystems
AT kenengwen survivalanalysesforpatientswithsurgicallyresectedpancreaticneuroendocrinetumorsbyworldhealthorganization2010gradingclassificationsandamericanjointcommitteeoncancer2010stagingsystems
AT zenglin survivalanalysesforpatientswithsurgicallyresectedpancreaticneuroendocrinetumorsbyworldhealthorganization2010gradingclassificationsandamericanjointcommitteeoncancer2010stagingsystems
AT zhangyi survivalanalysesforpatientswithsurgicallyresectedpancreaticneuroendocrinetumorsbyworldhealthorganization2010gradingclassificationsandamericanjointcommitteeoncancer2010stagingsystems
AT tanchunlu survivalanalysesforpatientswithsurgicallyresectedpancreaticneuroendocrinetumorsbyworldhealthorganization2010gradingclassificationsandamericanjointcommitteeoncancer2010stagingsystems
AT zhanghao survivalanalysesforpatientswithsurgicallyresectedpancreaticneuroendocrinetumorsbyworldhealthorganization2010gradingclassificationsandamericanjointcommitteeoncancer2010stagingsystems
AT maigang survivalanalysesforpatientswithsurgicallyresectedpancreaticneuroendocrinetumorsbyworldhealthorganization2010gradingclassificationsandamericanjointcommitteeoncancer2010stagingsystems
AT tianbole survivalanalysesforpatientswithsurgicallyresectedpancreaticneuroendocrinetumorsbyworldhealthorganization2010gradingclassificationsandamericanjointcommitteeoncancer2010stagingsystems
AT liuxubao survivalanalysesforpatientswithsurgicallyresectedpancreaticneuroendocrinetumorsbyworldhealthorganization2010gradingclassificationsandamericanjointcommitteeoncancer2010stagingsystems